|
Back to Home » October 2019 News » I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5 |
I-Mab Biopharma Receives IND Approval in China for Proprietary CD73 Antibody TJD5 |
October 04, 2019
SHANGHAI, Oct. 4, 2019 /PRNewswire/ -- I-Mab Biopharma ("I-Mab"), a China and U.S.-based clinical stage biopharmaceutical company exclusively focused on the discovery and development of novel or highly differentiated biologics in immuno-oncology and autoimmune diseases, today announced...
Source URL: https://www.prnewswire.com:443/news-releases/i-mab-biopharma-receives-ind-approval-in-china-for-proprietary-cd73-antibody-tjd5-300931152.html
|
|
|
|
